Rapid Plaque Progression Is Independently Associated With Hyperglycemia and Low HDL Cholesterol in Patients With Stable Coronary Artery Disease: A PARADIGM Study.
Humans
Male
Female
Middle Aged
Coronary Artery Disease
/ blood
Plaque, Atherosclerotic
Disease Progression
Aged
Computed Tomography Angiography
Coronary Angiography
/ methods
Cholesterol, HDL
/ blood
Hyperglycemia
/ blood
Time Factors
Blood Glucose
/ metabolism
Biomarkers
/ blood
Risk Assessment
Prognosis
Risk Factors
Prospective Studies
Predictive Value of Tests
cardiometabolic risk factors
cholesterol, HDL
computed tomography angiography
coronary artery disease
hyperglycemia
hypertension
metabolic syndrome
Journal
Circulation. Cardiovascular imaging
ISSN: 1942-0080
Titre abrégé: Circ Cardiovasc Imaging
Pays: United States
ID NLM: 101479935
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
medline:
16
7
2024
pubmed:
16
7
2024
entrez:
16
7
2024
Statut:
ppublish
Résumé
We assessed whether combinations of cardiometabolic risk factors independently predict coronary plaque progression (PP) and major adverse cardiovascular events in patients with stable coronary artery disease. Patients with known or suspected stable coronary artery disease (60.9±9.3 years, 55.4% male) undergoing serial coronary computed tomography angiographies (≥2 years apart), with clinical characterization and follow-up (N=1200), were analyzed from the PARADIGM study (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging). Plaque volumes measured in coronary segments (≥2 mm in diameter) were summed to provide whole heart plaque volume (mm In an interscan period of 3.2 years (interquartile range, 1.9), rapid PP occurred in 341 patients (28%). At multivariable analysis, the combination of cardiometabolic risk factors defined as metabolic syndrome predicted rapid PP (odds ratio, 1.51 [95% CI, 1.12-2.03]; In patients with stable coronary artery disease, the combination of hyperglycemia with low HDL-C is associated with rapid PP independently of other risk factors, baseline plaque burden, and treatment. The combination of hyperglycemia with high systemic blood pressure independently predicts the worse outcome beyond PP. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02803411.
Sections du résumé
BACKGROUND
UNASSIGNED
We assessed whether combinations of cardiometabolic risk factors independently predict coronary plaque progression (PP) and major adverse cardiovascular events in patients with stable coronary artery disease.
METHODS
UNASSIGNED
Patients with known or suspected stable coronary artery disease (60.9±9.3 years, 55.4% male) undergoing serial coronary computed tomography angiographies (≥2 years apart), with clinical characterization and follow-up (N=1200), were analyzed from the PARADIGM study (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging). Plaque volumes measured in coronary segments (≥2 mm in diameter) were summed to provide whole heart plaque volume (mm
RESULTS
UNASSIGNED
In an interscan period of 3.2 years (interquartile range, 1.9), rapid PP occurred in 341 patients (28%). At multivariable analysis, the combination of cardiometabolic risk factors defined as metabolic syndrome predicted rapid PP (odds ratio, 1.51 [95% CI, 1.12-2.03];
CONCLUSIONS
UNASSIGNED
In patients with stable coronary artery disease, the combination of hyperglycemia with low HDL-C is associated with rapid PP independently of other risk factors, baseline plaque burden, and treatment. The combination of hyperglycemia with high systemic blood pressure independently predicts the worse outcome beyond PP.
REGISTRATION
UNASSIGNED
URL: https://www.clinicaltrials.gov; Unique identifier: NCT02803411.
Identifiants
pubmed: 39012946
doi: 10.1161/CIRCIMAGING.123.016481
doi:
Substances chimiques
Cholesterol, HDL
0
Blood Glucose
0
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT02803411']
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e016481Déclaration de conflit d'intérêts
Dr Chang receives funding from the Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea funded by the Ministry of Science and ICT (grant No. 2012027176). Dr Min receives funding from GE Healthcare and serves on the scientific advisory board of Arineta and GE Healthcare. Dr Min also has an equity interest in and is an employee of Cleerly Inc. The other authors report no conflicts.